Q3 FY22 Earnings Presentation

Table of Contents Executive Portfolio Financial Guidance & Summary Highlights Highlights Assumptions ESG Appendix Medical Surgical MSD growth ex-vents despite Omicron-driven procedure and supply chain disruption Surgical Innovations (SI) Surgical Innovations HSD • HSD growth driven by advanced energy, stapling, and wound closure Product growth in stapling and energy driven by Tri-Staple TM Specialty Reloads and Signia™ intelligent stapling, Liga Sure™ Exact and Impact, as well as V-LocTM barbed suture in wound closure · COVID-19 resurgence in the U.S., Japan, and EMEA slowed procedure recovery in the quarter including staffing challenges and supply chain disruptions in resins and other supplies Surgical Robotics [Limited Market Release] Hugo™M RAS Platform • Completed first patient cases in EMEA with Hugo in combination with Touch Surgery™ Enterprise Performed multiple general surgery cases in Latin America and India, expanding on existing urologic and gynecologic use • Received regulatory approvals in Canada, Australia, and Israel • Expand URO U.S. clinical trial progressing in gaining ethics committee approvals through the Institutional Review Boards, conducting site personnel training, and moving towards clinical study site activation Continue to receive positive feedback on the open console with 3D visualization, our mobile, modular approach, and easy-to-access surgical video through Touch Surgery™ Enterprise Vizient, a leading healthcare performance improvement company in the U.S., has entered into an agreement with Medtronic to add Touch SurgeryTM Enterprise to its offerings for its vast membership 14 | Q3 FY22 earnings presentation | February 22, 2022 34% Respiratory, Gastrointestinal & Renal Medical Surgical 66% Surgical Innovations Medtronic

View entire presentation